NEW YORK – Massachusetts-based biotech Bicara Therapeutics officially launched on Monday with $40 million in seed funding from Indian pharma company Biocon and a pipeline of bifunctional antibody cancer immunotherapy candidates.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.